CRBP · Corbus Pharmaceuticals Holdings Inc. Common Stock
View on chartInsiders & Stakes
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 2,344,971 Shares held | 12/11/2025 | View profile |
| Yuval Cohen Chief Executive Officer | ▼ Sell | Open Market | 157,316 Shares held | 8/7/2026 | View profile |
| Dominic Smethurst Chief Medical Officer | ▼ Sell | Open Market | 89,790 Shares held | 3/2/2026 | View profile |
| Sean F. Moran Chief Financial Officer | ▼ Sell | Open Market | 84,694 Shares held | 8/7/2026 | View profile |
| Nishant C. Saxena Chief Business Officer | ▲ Buy | Open Market | 77,900 Shares held | 8/11/2026 | View profile |
| Leonardo Viana Nicacio Chief Medical Officer | ▲ Buy | Grant | 58,333 Shares held | 8/16/2026 | View profile |
| Ian Hodgson Chief Operating Officer | ▼ Sell | Open Market | 51,080 Shares held | 2/17/2026 | View profile |
| Millian Craig Stuart Chief Operating Officer | ▲ Buy | Open Market | 27,000 Shares held | 8/10/2022 | View profile |
| Winston Kung COO, CFO | ▼ Sell | Open Market | 12,140 Shares held | 6/10/2026 | View profile |
| Rachelle Suzanne Jacques Director | ▲ Buy | Grant | 11,383 Shares held | 5/19/2026 | View profile |
| Alan F. Holmer Director | ▲ Buy | Grant | 10,629 Shares held | 5/30/2025 | View profile |
| Yong Ben Chief Med & Dev Officer | ▼ Sell | Open Market | 9,383 Shares held | 9/14/2026 | View profile |
| Anne Altmeyer | ▼ Sell | Open Market | 7,579 Shares held | 6/10/2026 | View profile |
| Brent Pfeiffenberger President and CEO | ▲ Buy | Grant | 7,500 Shares held | 5/19/2026 | View profile |
| CATLIN AVERY W | ▲ Buy | Grant | 4,350 Shares held | 5/30/2024 | View profile |
| John Kenneth Jenkins | ▼ Sell | Open Market | 3,833 Shares held | 6/10/2026 | View profile |
| Salzmann Peter Chief Executive Officer | ▲ Buy | Grant | 2,783 Shares held | 5/30/2024 | View profile |
Transaction History
| Yong Ben | ▼ Sell | Open Market | 2,000 | $16K | 9/14/2026 |
| Leonardo Viana Nicacio | ▲ Buy | Grant | 58,333 | $0 | 8/16/2026 |
| Nishant C. Saxena | ▲ Buy | Open Market | 2,600 | $25K | 8/11/2026 |
| Yuval Cohen | ▼ Sell | Open Market | 17,000 | $171K | 8/7/2026 |
| Sean F. Moran | ▼ Sell | Open Market | 12,000 | $121K | 8/7/2026 |
| Winston Kung | ▼ Sell | Open Market | 2,026 | $16K | 6/10/2026 |
| Anne Altmeyer | ▼ Sell | Open Market | 2,412 | $19K | 6/10/2026 |
| John Kenneth Jenkins | ▼ Sell | Open Market | 4,800 | $38K | 6/10/2026 |
| Nishant C. Saxena | ▲ Buy | Open Market | 9,000 | $68K | 6/3/2026 |
| Nishant C. Saxena | ▲ Buy | Open Market | 4,500 | $33K | 6/2/2026 |
| Nishant C. Saxena | ▲ Buy | Grant | 58,300 | $0 | 5/21/2026 |
| Winston Kung | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 |
| Rachelle Suzanne Jacques | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 |
| John Kenneth Jenkins | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 |
| Anne Altmeyer | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 |
| Yong Ben | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 |
| Brent Pfeiffenberger | ▲ Buy | Grant | 7,500 | $0 | 5/19/2026 |
| Dominic Smethurst | ▼ Sell | Open Market | 6,097 | $51K | 3/2/2026 |
| Ian Hodgson | ▼ Sell | Open Market | 847 | $6K | 2/17/2026 |
| Sean F. Moran | ▼ Sell | Open Market | 4,701 | $37K | 2/13/2026 |
| Yuval Cohen | ▼ Sell | Open Market | 13,871 | $108K | 2/13/2026 |
| Dominic Smethurst | ▼ Sell | Open Market | 3,285 | $27K | 2/3/2026 |
| Ian Hodgson | ▼ Sell | Open Market | 2,415 | $20K | 2/3/2026 |
| Dominic Smethurst | ▲ Buy | Grant | 28,365 | $0 | 1/14/2026 |
| Sean F. Moran | ▲ Buy | Grant | 28,082 | $0 | 1/14/2026 |
| Yuval Cohen | ▲ Buy | Grant | 50,000 | $0 | 1/14/2026 |
| Ian Hodgson | ▲ Buy | Grant | 28,365 | $0 | 1/14/2026 |
| Cormorant Asset Management, LP | ▼ Sell | Open Market | 30,029 | $344K | 12/11/2025 |
| Yuval Cohen | ▲ Buy | Option Exercise | 8,973 | $38K | 10/27/2025 |
| Yuval Cohen | ▼ Sell | Open Market | 8,973 | $154K | 10/27/2025 |
| Yuval Cohen | ▲ Buy | Option Exercise | 18,660 | $79K | 10/24/2025 |
| Yuval Cohen | ▼ Sell | Open Market | 18,660 | $317K | 10/24/2025 |
| Sean F. Moran | ▲ Buy | Option Exercise | 12,981 | $55K | 10/24/2025 |
| Sean F. Moran | ▼ Sell | Open Market | 12,981 | $221K | 10/24/2025 |
| Anne Altmeyer | ▲ Buy | Option Exercise | 1,060 | $5K | 10/20/2025 |
| Anne Altmeyer | ▼ Sell | Open Market | 1,060 | $22K | 10/20/2025 |
| Winston Kung | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 |
| John Kenneth Jenkins | ▼ Sell | Open Market | 2,783 | $20K | 5/30/2025 |
| John Kenneth Jenkins | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 |
| Yong Ben | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 |
| Anne Altmeyer | ▼ Sell | Open Market | 1,392 | $10K | 5/30/2025 |
| Anne Altmeyer | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 |
| Alan F. Holmer | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 |
| Rachelle Suzanne Jacques | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 |
| Dominic Smethurst | ▼ Sell | Open Market | 6,393 | $43K | 3/6/2025 |
| Sean F. Moran | ▼ Sell | Open Market | 2,792 | $24K | 2/14/2025 |
| Yuval Cohen | ▼ Sell | Open Market | 7,134 | $62K | 2/14/2025 |
| Dominic Smethurst | ▲ Buy | Grant | 27,200 | $0 | 1/31/2025 |
| Sean F. Moran | ▲ Buy | Grant | 27,500 | $0 | 1/31/2025 |
| Yuval Cohen | ▲ Buy | Grant | 68,100 | $0 | 1/31/2025 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 45,085 | $788K | 9/20/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 25,943 | $476K | 9/20/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 66,088 | $1.3M | 9/20/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 139,551 | $2.8M | 9/20/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 47,564 | $1.0M | 9/20/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 25,769 | $573K | 9/20/2024 |
| Winston Kung | ▲ Buy | Grant | 5,566 | $0 | 8/16/2024 |
| Sean F. Moran | ▲ Buy | Option Exercise | 1,958 | $59K | 6/18/2024 |
| Sean F. Moran | ▼ Sell | Open Market | 1,958 | $82K | 6/18/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 11,667 | $350K | 6/18/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 11,667 | $493K | 6/18/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 1,770 | $25K | 6/18/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 1,770 | $75K | 6/18/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 2,322 | $10K | 6/18/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 2,322 | $98K | 6/18/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 7,179 | $303K | 6/18/2024 |
| Sean F. Moran | ▲ Buy | Option Exercise | 6,730 | $95K | 6/17/2024 |
| Sean F. Moran | ▼ Sell | Open Market | 6,730 | $315K | 6/17/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 9,333 | $280K | 6/17/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 9,333 | $430K | 6/17/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 1,770 | $8K | 6/17/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 1,770 | $81K | 6/17/2024 |
| Sean F. Moran | ▼ Sell | Open Market | 1,567 | $78K | 6/14/2024 |
| Sean F. Moran | ▲ Buy | Option Exercise | 7,788 | $33K | 6/14/2024 |
| Sean F. Moran | ▼ Sell | Open Market | 7,788 | $388K | 6/14/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 16,830 | $237K | 6/14/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 16,830 | $844K | 6/14/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 12,487 | $53K | 6/14/2024 |
| Yuval Cohen | ▼ Sell | Open Market | 12,487 | $626K | 6/14/2024 |
| Alan F. Holmer | ▲ Buy | Option Exercise | 1,667 | $50K | 6/14/2024 |
| Sean F. Moran | ▲ Buy | Option Exercise | 1,567 | $47K | 6/14/2024 |
| John Kenneth Jenkins | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| Rachelle Suzanne Jacques | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| Yong Ben | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| Alan F. Holmer | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| Anne Altmeyer | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| CATLIN AVERY W | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| Salzmann Peter | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 |
| Sean F. Moran | ▲ Buy | Option Exercise | 1,787 | $54K | 4/10/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 29,342 | $1.2M | 3/8/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 24,983 | $1.1M | 3/8/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 18,548 | $802K | 3/8/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 61,668 | $2.8M | 3/8/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 156,597 | $7.1M | 3/8/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 8,862 | $407K | 3/8/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 46,799 | $1.8M | 3/7/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 10,736 | $420K | 3/7/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 90,325 | $3.6M | 3/7/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 102,140 | $4.2M | 3/7/2024 |
| Dominic Smethurst | ▲ Buy | Grant | 50,000 | $0 | 2/27/2024 |
| Sean F. Moran | ▲ Buy | Grant | 40,176 | $0 | 2/12/2024 |
| Yuval Cohen | ▲ Buy | Grant | 73,947 | $0 | 2/12/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 750,000 | $14.3M | 2/2/2024 |
| Alan F. Holmer | ▲ Buy | Option Exercise | 629 | $3K | 1/26/2024 |
| Yuval Cohen | ▲ Buy | Option Exercise | 7,179 | $36K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 14,388 | $370K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 15,243 | $406K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 36,747 | $1.0M | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 31,028 | $894K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 29,244 | $860K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 2,654 | $82K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 4,125 | $131K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 3,866 | $126K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 18,055 | $609K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 31,549 | $1.1M | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 32,295 | $1.2M | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 16,484 | $602K | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 43,754 | $1.6M | 1/26/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 3,200 | $123K | 1/26/2024 |
| Millian Craig Stuart | ▲ Buy | Open Market | 5,000 | $1K | 8/10/2022 |
| Yuval Cohen | ▲ Buy | Open Market | 3,800 | $1K | 8/10/2022 |
| Sean F. Moran | ▲ Buy | Open Market | 20,000 | $5K | 8/10/2022 |
| Sean F. Moran | ▲ Buy | Open Market | 12,000 | $4K | 5/16/2022 |
| Yuval Cohen | ▲ Buy | Open Market | 10,500 | $3K | 5/16/2022 |
| Millian Craig Stuart | ▲ Buy | Open Market | 10,000 | $4K | 3/10/2022 |
| Sean F. Moran | ▲ Buy | Open Market | 15,000 | $6K | 3/10/2022 |
| Yuval Cohen | ▲ Buy | Open Market | 8,600 | $3K | 3/9/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.